 |
Vol.64 No.3 contents | Japanese/English |
 | Full Text of PDF (992K) Article in Japanese |
- Invited Review Article -
Clinical Development of Immune Checkpoint Inhibitor for Solid Tumors Other than Lung Cancer
Shigehisa Kitano1, Ippei Miyamoto1, Kana Kurokawa1, Eriko Miyawaki1, Hidenori Mizugaki11Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, Japan
It has been 10 years since immune checkpoint inhibitor (ICIs) were approved in Japan in 2014. ICIs block co-inhibitory receptors (immune checkpoint molecules) on T cells with antibodies, leading to the activation of cancer antigen-specific T cells to attack cancer. Internationally, the anti-CTLA-4 antibody ipilimumab was approved by the U.S. FDA (approved in Japan in 2015) for advanced malignant melanoma in March 2011, and the anti-PD-1 antibody nivolumab was approved in Japan in 2014. Subsequently, anti-PD-1 and anti-PD-L1 antibodies have been approved as single agents for multiple carcinomas, and combination therapies including ICI have been approved mainly as first-line therapy for various types of cancer. One of the recent trends is the approval of ICIs as perioperative cancer therapies for various early-stage cancers. This article reviews the clinical development of ICI for solid tumors other than lung cancer.
key words: Immune checkpoint inhibitor, CTLA-4, PD-1, PD-L1, Combination cancer immunotherapy
JJLC 64 (3): 158-167, 2024
